Status:
TERMINATED
Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis
Lead Sponsor:
Cantonal Hospital of St. Gallen
Collaborating Sponsors:
Swiss Federal Institute of Technology
Insel Gruppe AG, University Hospital Bern
Conditions:
Pulmonary Inflammation
Cystic Fibrosis
Eligibility:
All Genders
6-20 years
Phase:
NA
Brief Summary
Pulmonary inflammation is an independent risk factor for disease progression in cystic fibrosis patients (CF). Yet, no effective treatment is known to reduce this detrimental inflammation. Dysbiosis o...
Eligibility Criteria
Inclusion
- moderate to severe CF disease
Exclusion
- acute gastroenteritis 2 weeks prior to inclusion
- chronic disease other than CF (except CF associated disorders)
- oral or parenteral antibiotics 2 weeks prior to inclusion
- systemic steroids 4 weeks prior to inclusion
- any probiotic intake
Key Trial Info
Start Date :
February 22 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01837355
Start Date
February 22 2013
End Date
December 31 2018
Last Update
June 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens's Hospital of Eastern Switzerland
Sankt Gallen, Canton of St. Gallen, Switzerland, 9008